Covid-19-induced pulmonary hypertension in children, and the use of phosphodiesterase-5 inhibitors

Herlina Dimiati,Iflan Naufal,Dimas Arya Umara

doi:10.12688/f1000research.53966.1

Herlina Dimiati, Iflan Naufal + Show 1 more

Open Access

https://doi.org/10.12688/f1000research.53966.1

Copy DOI

Journal: F1000Research	Publication Date: Aug 11, 2021
License type: CC BY 4.0

Affiliation: Syiah Kuala University

Abstract

Respiratory tract infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first occurred in Wuhan, China, in December 2019 and was declared as a pandemic by WHO. The interaction between the 2019 coronavirus disease (COVID-19) and pulmonary hypertension (PH) in children is not widely known. Phosphodiesterase-5 inhibitors (PDEI), one class of drugs used to treat PH, including sildenafil, can suppress angiotensin type I (AT-1) receptor expression. Furthermore, it reduces proinflammatory cytokines and infiltrates the alveolar, inhibits endothelial and smooth muscle transition, mesenchymal cells in the pulmonary artery, and prevents clotting and thrombosis complications. Sildenafil has shown positive effects by diverting the blood flow to the lungs in such a way that ventilation is adequate and can also be anti-inflammatory.

Highlights

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
Some putative instruments related with pulmonary hypertension (PH) in COVID-19 start when the limiting of the ACE2 receptor and protein spike of SARS-CoV-2, bringing about serious provocative responses prompting diffuse pneumonic alveolar harm, apoplexy, endothelitis, angiogenesis and endothelial brokenness.[31,32,33,34,35,36,37]
Hemodynamic status in patients with acute respiratory disease syndrome (ARDS) is comparable with expansion in the diastolic pneumonic slope >7 and pneumonic vascular obstruction (PVR) >3 Wood units

Summary

11 Aug 2021 report

Any reports and responses or comments on the article can be found at the end of the article. Keywords COVID-19, pulmonary hypertension, Phosphodiesterase-5 inhibitors, Children. This article is included in the Emerging Diseases and Outbreaks gateway. This article is included in the Coronavirus collection

Introduction

Conclusion

Team NCPERE

31. Das BB: COVID-19 and Pulmonary Hypertension in Children

45. Beghetti M

Findings

49. Haworth SG